GlassScriptPhysician profile
Elisa E Vinyard
NPI 1477525152
$679.71
in general payments reported to CMS, 2019-2025
18 companies · $21.87 in 2025
The $21.87 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $167 · 2021: $18.04 · 2022: $51.04 · 2023: $241 · 2024: $77.64 · 2025: $21.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $155.04 | 2019-2023 | Repatha |
| Teva Pharmaceuticals USA, INC. | $58.01 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $49.41 | 2023 | Rebyota |
| Novo Nordisk INC | $42.36 | 2024 | Rybelsus, Wegovy |
| Pfizer INC. | $41.65 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $39.48 | 2019 | |
| Daiichi Sankyo INC. | $34.79 | 2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.40 | 2020 | |
| Baudax Bio INC. | $31.56 | 2022 | |
| Ucb, INC. | $31.06 | 2020 | |
| Sunovion Pharmaceuticals INC. | $28.00 | 2019 | |
| Organogenesis INC. | $24.90 | 2020 | |
| Amarin Pharma, INC. | $24.51 | 2020 | |
| Janssen Pharmaceuticals, INC | $20.18 | 2023 | Xarelto |
| Sanofi Pasteur INC. | $19.48 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $17.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.50 | 2024 | Lokelma |
| Mylan Specialty L.P. | $13.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisa Vinyard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.